Loading...
Loading...
Merck
MRK
today announced results from the pivotal KEYNOTE-010 study, the first
study of its kind to evaluate the potential of an immunotherapy compared
to chemotherapy based on prospective measurement of PD-L1 expression in
patients with advanced non-small cell lung cancer (NSCLC). In the Phase
2/3 study, KEYTRUDA® (pembrolizumab), Merck's anti-PD-1
(programmed death receptor-1) therapy, significantly improved overall
survival (OS) compared to chemotherapy in patients with any level of
PD-L1 expression, as defined by a tumor proportion score (TPS) of 1
percent or more. The results were published in The Lancet and
will be presented at the European Society for Medical Oncology (ESMO)
Asia 2015 Congress.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in